Non-Small Cell Lung Cancer Drugs Market Worth $9.37bn In 2021

LONDON - Oct. 19, 2017 - PRLog -- Visiongain's new report Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other indicates that the non-small cell lung cancer drugs market will see $9.37bn in spending in 2021.

The Non-Small Cell Lung Cancer (NSCLC) Drugs market is estimated at $7.86bn in 2016 and is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.2% during the full forecast period. In 2016, the chemotherapy segment generated a revenue of $3.28bn and represented 41.7% of the total NSCLC drugs market

The lead analyst of this report said "We predict growth throughout the next ten years, although growth will be restrained in the second half of the forecast period, mainly due to patent expiries of leading therapies.  Exciting new therapies, including the new class of immunotherapies, is gradually expected to reinvigorate growth in the years after the forecast period of this report. The years 2021-2027) represent a gap where revenues from the traditional leaders of the market will fall due to generic and biosimilar competition, and whilst pipeline therapies and other drivers will preserve revenues during this time, and even allow for slight growth, they won't be able to sustain the growth seen in the first half of the forecast period."

The 172-page report contains 133 charts that add visual analysis in order to explain the developing trends within the non-small cell lung cancer drugs market.

Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the non-small cell lung cancer drugs market market and its leading therapeutic segments: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, and Other.

This report also provides revenue forecast for 11 leading drugs in the NSCLC market and discusses late-stage drug candidates that are currently being developed.

The 172-page report offers market forecasts for the leading regional and national markets: the US, Germany, France, The UK, Italy, Spain, Japan, China, Brazil, Russia, India, and RoW. Moreover, our study also includes a SWOT of this industry and market.

The report Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other report will be of value to anyone who wants to better understand the non-small cell lung cancer drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the non-small cell lung cancer drugs market market.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com (mailto:sara.peerun@visiongainglobal.com) or call her on +44 (0) 207 336 6100.

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.